NASDAQ:CBST - Cubist Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Receive CBST News and Ratings via Email

Sign-up to receive the latest news and ratings for CBST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:CBST
CUSIP22967810
Phone+1-781-8608660

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Cubist Pharmaceuticals (NASDAQ:CBST) Frequently Asked Questions

What is Cubist Pharmaceuticals' stock symbol?

Cubist Pharmaceuticals trades on the NASDAQ under the ticker symbol "CBST."

How were Cubist Pharmaceuticals' earnings last quarter?

Cubist Pharmaceuticals Inc (NASDAQ:CBST) released its quarterly earnings results on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.54. The biopharmaceutical company earned $309.20 million during the quarter, compared to analyst estimates of $305.50 million. Cubist Pharmaceuticals's revenue was up 16.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.41 EPS. View Cubist Pharmaceuticals' Earnings History.

Has Cubist Pharmaceuticals been receiving favorable news coverage?

Press coverage about CBST stock has been trending neutral this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cubist Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future.

How do I buy shares of Cubist Pharmaceuticals?

Shares of CBST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cubist Pharmaceuticals' official website?

The official website for Cubist Pharmaceuticals is http://www.cubist.com/.

How can I contact Cubist Pharmaceuticals?

Cubist Pharmaceuticals' mailing address is 65 Hayden Ave, LEXINGTON, MA 02421-7994, United States. The biopharmaceutical company can be reached via phone at +1-781-8608660.


MarketBeat Community Rating for Cubist Pharmaceuticals (NASDAQ CBST)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  472
MarketBeat's community ratings are surveys of what our community members think about Cubist Pharmaceuticals and other stocks. Vote "Outperform" if you believe CBST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/19/2019 by MarketBeat.com Staff

Featured Article: Portfolio Manager

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel